AIMM Therapeutics

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Developer of an antibodies experimental platform designed to empower biological antibodies and other therapeutic proteins. The company's platform is agile, multi-objective, and data-driven and integrates a wet laboratory with artificial intelligence and machine learning techniques to design antibodies, enabling drug developers to create antibodies and undertake novel biotherapeutic designs.

Developer of immuno-personalized diagnosis devices designed to detect bacterial and viral infections. The company's devices distinguish between bacterial and viral infections based on patients' immune responses to different infection types, enabling physicians to get rapid and actionable clinical information that guides them to make informed antibiotic treatment decisions.